InStride Health
United States
- Boston
- 02/04/2024
- Series B
- $30,000,000
InStride Health is a specialty pediatric anxiety/OCD outpatient treatment program that uses evidence-based care (CBT, ACT, DBT) with an emphasis on exposure therapy. Our highly-experienced care team including a psychiatrist, therapist and exposure coach, teaches patients and families the skills and strategies needed to quickly get their lives back on track. InStride provides insurance-based access to a human-first, fully virtual personalized treatment plan that fits into your life and has proven as effective as in-person treatment for anxiety/OCD. More than a continuum of care—InStride is a pathway to a healthier life and hope for a more promising future.
- Industry Mental Health Care
- Website https://www.instride.health/
- LinkedIn https://www.linkedin.com/company/instride-health/
Related People
John VoithFounder
United States -
Greater Boston
With over 14 years of experience in health care entrepreneurship, I am passionate about creating mission-oriented companies that deliver high-quality, accessible, and patient-centered care. Currently, I am the CEO and Co-Founder of InStride Health, an outpatient treatment provider for kids, teens, and young adults experiencing moderate to severe anxiety and/or OCD. In collaboration with McLean Hospital, we offer comprehensive, evidence-based therapies that are covered by insurance and tailored to each patient's needs and goals.
Before InStride, I led Virtudent, a teledentistry company that brought preventive dental care to workplaces and the community. I scaled the company from a start-up to a national leader in oral health innovation, serving thousands of patients and partners across the US. I also have a strong background in interoperability, strategy, and business development, having held various leadership roles at athenahealth and IMS Health. I hold an MBA from The Wharton School, an MPA from Harvard Kennedy School, and a BA in Biology and Public Policy from Harvard University.
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)